Bicara Therapeutics (NASDAQ:BCAX) Trading Down 4.6% - Should You Sell?

Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report)'s share price traded down 4.6% during mid-day trading on Wednesday . The company traded as low as $12.16 and last traded at $12.01. 234,658 shares changed hands during trading, a decline of 60% from the average session volume of 583,237 shares. The stock had previously closed at $12.58.

Analyst Ratings Changes

Several research firms have recently weighed in on BCAX. HC Wainwright lowered their price objective on shares of Bicara Therapeutics from $44.00 to $41.00 and set a "buy" rating for the company in a research note on Friday, May 16th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $13.01 price target on shares of Bicara Therapeutics in a research note on Thursday, March 13th. Wedbush reiterated an "outperform" rating and set a $30.00 price objective on shares of Bicara Therapeutics in a report on Friday, May 23rd. Stifel Nicolaus set a $48.00 target price on Bicara Therapeutics in a research note on Thursday, March 27th. Finally, Wells Fargo & Company upgraded Bicara Therapeutics from an "underweight" rating to an "equal weight" rating and set a $8.00 price target on the stock in a report on Friday, May 23rd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $31.86.

Bicara Therapeutics Stock Performance

The stock's fifty day simple moving average is $12.37 and its 200-day simple moving average is $13.97.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.40) by ($0.28). As a group, sell-side analysts anticipate that Bicara Therapeutics Inc. will post -2.59 earnings per share for the current fiscal year.

Institutional Trading of Bicara Therapeutics

A number of hedge funds have recently bought and sold shares of the business. Rhumbline Advisers grew its stake in Bicara Therapeutics by 21.1% in the 1st quarter. Rhumbline Advisers now owns 23,018 shares of the company's stock valued at $300,000 after purchasing an additional 4,010 shares during the period. Woodline Partners LP raised its position in Bicara Therapeutics by 26.5% in the first quarter. Woodline Partners LP now owns 348,690 shares of the company's stock worth $4,543,000 after acquiring an additional 72,998 shares during the period. AQR Capital Management LLC bought a new stake in Bicara Therapeutics in the first quarter worth about $248,000. Vestal Point Capital LP grew its position in shares of Bicara Therapeutics by 290.0% during the 1st quarter. Vestal Point Capital LP now owns 2,768,975 shares of the company's stock valued at $36,080,000 after acquiring an additional 2,058,975 shares during the period. Finally, Braidwell LP grew its holdings in Bicara Therapeutics by 8.1% during the first quarter. Braidwell LP now owns 2,162,803 shares of the company's stock valued at $28,181,000 after purchasing an additional 162,144 shares during the period.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.